Rekombinanter OC126 (Abagovomab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter OC126 (Abagovomab Biosimilar) Antikörper (ABIN7538052)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
-
-
Expressionssystem
- Mammalian cells
-
Verwendungszweck
- Abagovomab Biosimilar - Anti-idiotope of anti-Mus musculus monoclonal antibody OC126 mAb - Research Grade
-
Produktmerkmale
- Antibody Type: idiotypic IgG1-kappa
-
Aufreinigung
- Recombinant antibody expressed in mammalien cells and purified.
-
Reinheit
- > 85%
-
Isotyp
- IgG1 kappa
-
-
-
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Buffer
- PBS buffer PH7.5
-
Lagerung
- -80 °C
-
Informationen zur Lagerung
- store at -80°C
-
-
- OC126 (Abagovomab Biosimilar)
-
Substanzklasse
- Biosimilar
-
Hintergrund
- Abagovomab is a murine monoclonal anti-idiotypic antibody (MW: 165-175 kDa), produced by a mouse hybridoma and generated against OC125, which serves to functionally imitate the human cancer antigen 125 (CA-125). Abagovomab has been developed by the pharmaceutical company Menarini for the treatment of ovarian cancer. It (ab2) shows high affinity for the paratope of ab1, and binding of ab2 to Ab1 is almost completely inhibited (93%) by the nominal antigen. The administration of F(ab')2 fragments of abagovomab to rats produces anti-CA-125 immunity with the production of IgG and IgM anti-anti-idiotypic antibodies (ab3) that bind both to abagovomab and CA-125. Non-MHC restricted cell-mediated cytotoxicity for NIH OVCAR3 cell lines is also demonstrated.
-
CAS-Nummer
- 792921-10-9
Target
-